Evolva Holding (ELVAF) Price & Analysis

11 Followers

ELVAF Stock Chart & Stats

$2.15

$0.00(0.00%)

At close: Jun 23 4:00 PM EDT

$2.15

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.90 - $2.15

Previous CloseN/A

Volume20.00

Average Volume (3M)40.00

Market Cap

$19.21M

Enterprise Value$6.22M

Total Cash (Recent Filing)$5.61M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.64

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding7,230,626

10 Day Avg. Volume120

30 Day Avg. Volume40

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.98

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.32

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-16.93

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)3.15

Revenue Forecast (FY)$76.74M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe lack of debt from 2023–2025 materially lowers fixed financing costs and preserves strategic flexibility. For a biotech with uneven cash generation, low leverage reduces insolvency risk, limits interest expense drain, and extends runway to pursue partnerships or restructuring without immediate debt-servicing pressure.

Narrowing Cash BurnOperating cash burn narrowing in 2024–2025 versus prior years indicates improved cost discipline and extends runway. If sustained, lower cash consumption meaningfully reduces near-term financing needs, improving the odds management can execute a recovery or pivot to rebuild revenues without urgent dilutive raises.

Demonstrated Ability To Be Profitable (2024)Recording positive net income and EBIT/EBITDA in 2024 shows the business can reach profitability under certain conditions. This demonstrates structural operational levers or cost base adjustments exist, supporting the view that, with restored revenue, the company could sustain profitably rather than being permanently loss-making.

Bears Say

Zero Reported Revenue (2024–2025)Reporting zero revenue in 2024–2025 eliminates a durable operating foundation and means no ongoing sales-driven earnings engine. This structural deficiency forces reliance on financing, asset sales, or one-off items, and substantially raises execution risk until a sustainable revenue stream is re-established.

Chronic Negative Operating And Free Cash FlowOperating and free cash flow were negative across 2020–2025, indicating persistent cash consumption. Such chronic deficits erode reserves, force repeated external funding or asset depletion, and constrain investment in R&D and commercialization needed to rebuild durable revenue and margins over the medium term.

Shrinking Capital Base And Volatile ReturnsA materially shrinking equity and asset base reduces financial cushions and increases reliance on external capital. Volatile ROE signals inconsistent value creation and execution risk, complicating long-term planning and increasing dilution or solvency risk absent a sustainable revenue turnaround.

Evolva Holding News

EvoNext Wins Shareholder Backing for Governance Changes to Pursue Reverse Takeover

Evolva Holding ( ($CH:EVE) ) has issued an update. Shareholders of EvoNext Holdings SA approved all board proposals...

2M ago

EvoNext posts low 2025 cash burn as it pursues reverse takeover and eyes arbitration upside

An update from Evolva Holding ( ($CH:EVE) ) is now available. EvoNext Holdings SA has released its 2025...

3M ago

EvoNext Holdings Reports 2025 Half-Year Financials and Strategic M&A Plans

Evolva Holding ( ($CH:EVE) ) just unveiled an update. EvoNext Holdings SA, formerly Evolva Holding SA, has released...

11M ago

Evolva Holding SA Rebrands to EvoNext Holdings SA

The latest announcement is out from Evolva Holding ( ($CH:EVE) ). Evolva Holding SA, a company listed on...

1y ago

ELVAF FAQ

What was Evolva Holding’s price range in the past 12 months?

Evolva Holding lowest stock price was $0.90 and its highest was $2.15 in the past 12 months.

What is Evolva Holding’s market cap?

Evolva Holding’s market cap is $19.21M.

When is Evolva Holding’s upcoming earnings report date?

Evolva Holding’s upcoming earnings report date is Aug 26, 2026 which is in 28 days.

How were Evolva Holding’s earnings last quarter?

Evolva Holding released its earnings results on Apr 29, 2026. The company reported -$0.049 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.049.

Is Evolva Holding overvalued?

According to Wall Street analysts Evolva Holding’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Evolva Holding pay dividends?

Evolva Holding does not currently pay dividends.

What is Evolva Holding’s EPS estimate?

Evolva Holding’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Evolva Holding have?

Evolva Holding has 7,230,626 shares outstanding.

What happened to Evolva Holding’s price movement after its last earnings report?

Evolva Holding reported an EPS of -$0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Evolva Holding?

Currently, no hedge funds are holding shares in ELVAF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Evolva Holding

EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.